| Ipratropium Bromide Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Ipratropium Bromide 0.02% | solution | inhalation | 100.0 milliliter(s) | OTC |
| Ipratropium Bromide - | powder | compounding | 100.0 gram(s) | OTC |
Alabama settles with 2 drug firms - Montgomery Advertiser
Its claim against Dey involved a number of drugs prescribed primarily for pulmonary diseases and asthma, such as albuterol sulfate and ipratropium bromide. ...
Thu Jan 10 05:04:08 -0500 2008
Takeda, Dey Pay Alabama $6.75 Million in Medicaid Lawsuit - FDA news (subscription)
... pulmonary diseases and asthma, such as albuterol sulfate and ipratropium bromide, Alabama Attorney General Troy King said in announcing the settlement. ...
Fri Jan 18 17:43:25 -0500 2008
State Settles with Two Pharmaceutical Companies - WSFA
... claim against Dey involved a number of drugs prescribed primarily for pulmonary diseases and asthma, such as Albuterol Sulfate and Ipratropium Bromide. ...
Wed Jan 09 17:37:38 -0500 2008
ipratropium bromide - The bromide salt form of ipratropium, a synthetic derivative of the alkaloid atropine with anticholinergic properties. Ipratropium antagonizes the actions of acetylcholine at parasympathetic, postganglionic, effector-cell junctions. When inhaled, ipratropium binds competitively to cholinergic receptors in the bronchial smooth muscle thereby blocking the bronchoconstrictor actions of the acetylcholine (Ach) mediated vagal impulses. Inhibition of the vagal tone leads to dilation of the large central airways resulting in bronchodilation.